阿尔茨海默病的基线微胶质细胞激活与脑淀粉样变性和纵向认知能力下降相关。

IF 7.8 1区 医学 Q1 CLINICAL NEUROLOGY Neurology® Neuroimmunology & Neuroinflammation Pub Date : 2022-03-08 Print Date: 2022-05-01 DOI:10.1212/NXI.0000000000001152
Qing Wang, Gengsheng Chen, Suzanne E Schindler, Jon Christensen, Nicole S McKay, Jingxia Liu, Sicheng Wang, Zhexian Sun, Jason Hassenstab, Yi Su, Shaney Flores, Russ Hornbeck, Lisa Cash, Carlos Cruchaga, Anne M Fagan, Zhude Tu, John C Morris, Mark A Mintun, Yong Wang, Tammie L S Benzinger
{"title":"阿尔茨海默病的基线微胶质细胞激活与脑淀粉样变性和纵向认知能力下降相关。","authors":"Qing Wang, Gengsheng Chen, Suzanne E Schindler, Jon Christensen, Nicole S McKay, Jingxia Liu, Sicheng Wang, Zhexian Sun, Jason Hassenstab, Yi Su, Shaney Flores, Russ Hornbeck, Lisa Cash, Carlos Cruchaga, Anne M Fagan, Zhude Tu, John C Morris, Mark A Mintun, Yong Wang, Tammie L S Benzinger","doi":"10.1212/NXI.0000000000001152","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>This study aims to quantify microglial activation in individuals with Alzheimer disease (AD) using the 18-kDa translocator protein (TSPO) PET imaging in the hippocampus and precuneus, the 2 AD-vulnerable regions, and to evaluate the association of baseline neuroinflammation with amyloidosis, tau, and longitudinal cognitive decline.</p><p><strong>Methods: </strong>Twenty-four participants from the Knight Alzheimer Disease Research Center (Knight ADRC) were enrolled and classified into stable cognitively normal, progressor, and symptomatic AD groups based on clinical dementia rating (CDR) at 2 or more clinical assessments. The baseline TSPO radiotracer [11C]PK11195 was used to image microglial activation. Baseline CSF concentrations of Aβ42, Aβ42/Aβ40 ratio, tau phosphorylated at position 181 (p-tau181), and total tau (t-tau) were measured. Clinical and cognitive decline were examined with longitudinal CDR and cognitive composite scores (Global and Knight ADRC-Preclinical Alzheimer Cognitive Composite [Knight ADRC-PACC] Score).</p><p><strong>Results: </strong>Participants in the progressor and symptomatic AD groups had significantly elevated [11C]PK11195 standard uptake value ratios (SUVRs) in the hippocampus but not in the precuneus region. In the subcohort with CSF biomarkers (16 of the 24), significant negative correlations between CSF Aβ42 or Aβ42/Aβ40 and [11C]PK11195 SUVR were observed in the hippocampus and precuneus. No correlations were observed between [11C]PK11195 SUVR and CSF p-tau181 or t-tau at baseline in those regions. Higher baseline [11C]PK11195 SUVR averaged in the whole cortical regions predicted longitudinal decline on cognitive tests.</p><p><strong>Discussion: </strong>Microglial activation is increased in individuals with brain amyloidosis and predicts worsening cognition in AD.</p><p><strong>Classification of evidence: </strong>This study provides Class II evidence that in patients with AD, higher baseline [11C]PK11195 SUVR averaged in the whole cortical regions was associated with longitudinal decline on cognitive tests.</p>","PeriodicalId":19472,"journal":{"name":"Neurology® Neuroimmunology & Neuroinflammation","volume":"9 3","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2022-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/73/NEURIMMINFL2021039348.PMC8906187.pdf","citationCount":"11","resultStr":"{\"title\":\"Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease.\",\"authors\":\"Qing Wang, Gengsheng Chen, Suzanne E Schindler, Jon Christensen, Nicole S McKay, Jingxia Liu, Sicheng Wang, Zhexian Sun, Jason Hassenstab, Yi Su, Shaney Flores, Russ Hornbeck, Lisa Cash, Carlos Cruchaga, Anne M Fagan, Zhude Tu, John C Morris, Mark A Mintun, Yong Wang, Tammie L S Benzinger\",\"doi\":\"10.1212/NXI.0000000000001152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>This study aims to quantify microglial activation in individuals with Alzheimer disease (AD) using the 18-kDa translocator protein (TSPO) PET imaging in the hippocampus and precuneus, the 2 AD-vulnerable regions, and to evaluate the association of baseline neuroinflammation with amyloidosis, tau, and longitudinal cognitive decline.</p><p><strong>Methods: </strong>Twenty-four participants from the Knight Alzheimer Disease Research Center (Knight ADRC) were enrolled and classified into stable cognitively normal, progressor, and symptomatic AD groups based on clinical dementia rating (CDR) at 2 or more clinical assessments. The baseline TSPO radiotracer [11C]PK11195 was used to image microglial activation. Baseline CSF concentrations of Aβ42, Aβ42/Aβ40 ratio, tau phosphorylated at position 181 (p-tau181), and total tau (t-tau) were measured. Clinical and cognitive decline were examined with longitudinal CDR and cognitive composite scores (Global and Knight ADRC-Preclinical Alzheimer Cognitive Composite [Knight ADRC-PACC] Score).</p><p><strong>Results: </strong>Participants in the progressor and symptomatic AD groups had significantly elevated [11C]PK11195 standard uptake value ratios (SUVRs) in the hippocampus but not in the precuneus region. In the subcohort with CSF biomarkers (16 of the 24), significant negative correlations between CSF Aβ42 or Aβ42/Aβ40 and [11C]PK11195 SUVR were observed in the hippocampus and precuneus. No correlations were observed between [11C]PK11195 SUVR and CSF p-tau181 or t-tau at baseline in those regions. Higher baseline [11C]PK11195 SUVR averaged in the whole cortical regions predicted longitudinal decline on cognitive tests.</p><p><strong>Discussion: </strong>Microglial activation is increased in individuals with brain amyloidosis and predicts worsening cognition in AD.</p><p><strong>Classification of evidence: </strong>This study provides Class II evidence that in patients with AD, higher baseline [11C]PK11195 SUVR averaged in the whole cortical regions was associated with longitudinal decline on cognitive tests.</p>\",\"PeriodicalId\":19472,\"journal\":{\"name\":\"Neurology® Neuroimmunology & Neuroinflammation\",\"volume\":\"9 3\",\"pages\":\"\"},\"PeriodicalIF\":7.8000,\"publicationDate\":\"2022-03-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/73/NEURIMMINFL2021039348.PMC8906187.pdf\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology® Neuroimmunology & Neuroinflammation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1212/NXI.0000000000001152\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/5/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology® Neuroimmunology & Neuroinflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/NXI.0000000000001152","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/5/1 0:00:00","PubModel":"Print","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 11

摘要

背景和目的:本研究旨在使用海马和楔前叶(AD的两个易感区域)的18kDa转运蛋白(TSPO)PET成像来量化阿尔茨海默病(AD)患者的小胶质细胞激活,并评估基线神经炎症与淀粉样变性、tau和纵向认知能力下降的关系。方法:来自奈特阿尔茨海默病研究中心(Knight ADRC)的24名参与者被纳入研究,并根据2次或2次以上临床评估的临床痴呆评分(CDR)分为认知正常、进展期和症状性AD组。基线TSPO放射性示踪剂[11C]PK11195用于对小胶质细胞活化进行成像。测量Aβ42、Aβ42/Aβ40比值、181位磷酸化的tau(p-tau181)和总tau(t-tau)的基线CSF浓度。通过纵向CDR和认知复合评分(Global和Knight ADRC临床前阿尔茨海默病认知复合评分[Night ADRC-PACC]评分)检查临床和认知能力下降。结果:进展期和症状性AD组的参与者海马[11C]PK11195标准摄取值比(SUVRs)显著升高,但楔前区没有。在具有CSF生物标志物的亚群中(24个中的16个),在海马和楔前叶中观察到CSF Aβ42或Aβ42/Aβ40与[11C]PK11195SUVR之间的显著负相关。在这些区域的[11C]PK11195SUVR与基线时的CSF p-tau181或t-tau之间没有观察到相关性。较高的基线[11C]PK11195SUVR在整个皮层区域的平均值预测了认知测试的纵向下降。讨论:脑淀粉样变性患者的微胶质细胞激活增加,可预测AD患者认知能力的恶化。证据分类:本研究提供了II类证据,证明AD患者整个皮层区域平均基线[11C]PK11195SUVR较高与认知测试的纵向下降相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease.

Background and objectives: This study aims to quantify microglial activation in individuals with Alzheimer disease (AD) using the 18-kDa translocator protein (TSPO) PET imaging in the hippocampus and precuneus, the 2 AD-vulnerable regions, and to evaluate the association of baseline neuroinflammation with amyloidosis, tau, and longitudinal cognitive decline.

Methods: Twenty-four participants from the Knight Alzheimer Disease Research Center (Knight ADRC) were enrolled and classified into stable cognitively normal, progressor, and symptomatic AD groups based on clinical dementia rating (CDR) at 2 or more clinical assessments. The baseline TSPO radiotracer [11C]PK11195 was used to image microglial activation. Baseline CSF concentrations of Aβ42, Aβ42/Aβ40 ratio, tau phosphorylated at position 181 (p-tau181), and total tau (t-tau) were measured. Clinical and cognitive decline were examined with longitudinal CDR and cognitive composite scores (Global and Knight ADRC-Preclinical Alzheimer Cognitive Composite [Knight ADRC-PACC] Score).

Results: Participants in the progressor and symptomatic AD groups had significantly elevated [11C]PK11195 standard uptake value ratios (SUVRs) in the hippocampus but not in the precuneus region. In the subcohort with CSF biomarkers (16 of the 24), significant negative correlations between CSF Aβ42 or Aβ42/Aβ40 and [11C]PK11195 SUVR were observed in the hippocampus and precuneus. No correlations were observed between [11C]PK11195 SUVR and CSF p-tau181 or t-tau at baseline in those regions. Higher baseline [11C]PK11195 SUVR averaged in the whole cortical regions predicted longitudinal decline on cognitive tests.

Discussion: Microglial activation is increased in individuals with brain amyloidosis and predicts worsening cognition in AD.

Classification of evidence: This study provides Class II evidence that in patients with AD, higher baseline [11C]PK11195 SUVR averaged in the whole cortical regions was associated with longitudinal decline on cognitive tests.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.60
自引率
2.30%
发文量
219
审稿时长
8 weeks
期刊介绍: Neurology Neuroimmunology & Neuroinflammation is an official journal of the American Academy of Neurology. Neurology: Neuroimmunology & Neuroinflammation will be the premier peer-reviewed journal in neuroimmunology and neuroinflammation. This journal publishes rigorously peer-reviewed open-access reports of original research and in-depth reviews of topics in neuroimmunology & neuroinflammation, affecting the full range of neurologic diseases including (but not limited to) Alzheimer's disease, Parkinson's disease, ALS, tauopathy, and stroke; multiple sclerosis and NMO; inflammatory peripheral nerve and muscle disease, Guillain-Barré and myasthenia gravis; nervous system infection; paraneoplastic syndromes, noninfectious encephalitides and other antibody-mediated disorders; and psychiatric and neurodevelopmental disorders. Clinical trials, instructive case reports, and small case series will also be featured.
期刊最新文献
"Lupus Myelitis" Revisited: A Retrospective Single-Center Study of Myelitis Associated With Rheumatologic Disease. Missing Full Disclosures. Obesity Affects Disease Activity and Progression, Cognitive Functioning, and Quality of Life in People With Multiple Sclerosis. Proteomic Profiling and Pathophysiological Implications in Multiple Sclerosis. Proteomics Reveals Age as Major Modifier of Inflammatory CSF Signatures in Multiple Sclerosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1